Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) (2021)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1177/17588359211022905
- Subjects: ESTUDOS PROSPECTIVOS; NEOPLASIAS PULMONARES (TERAPIA); SOBREVIVÊNCIA LIVRE DE DOENÇA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Therapeutic advances in medical oncology
- ISSN: 1758-8340
- Volume/Número/Paginação/Ano: v. 13, article ID 17588359211022900, 14p, 2021
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
GROSSI, Francesco et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, v. 13, 2021Tradução . . Disponível em: https://doi.org/10.1177/17588359211022905. Acesso em: 18 fev. 2026. -
APA
Grossi, F., Jaskiewicz, P., Ferreira, M., Czyzewicz, G., Kowalski, D., Ciuffreda, L., et al. (2021). Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic advances in medical oncology, 13. doi:10.1177/17588359211022905 -
NLM
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2026 fev. 18 ] Available from: https://doi.org/10.1177/17588359211022905 -
Vancouver
Grossi F, Jaskiewicz P, Ferreira M, Czyzewicz G, Kowalski D, Ciuffreda L, Garcia-gomez R, Caruso S, Bosch-barrera J, Gautier S, Castro Junior G de C. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03) [Internet]. Therapeutic advances in medical oncology. 2021 ; 13[citado 2026 fev. 18 ] Available from: https://doi.org/10.1177/17588359211022905 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Non-gastrointestinal stromal tumours soft tissue sarcomas: an update
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Epidemiologia do câncer de pulmão
- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
- Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus
- The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer
- Desenvolvimento de fármacos: pesquisa clínica e medicina de precisão
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Expressão da proteína ERCC1 (Excision Repair Cross Complementing Group 1), do seu RNA mensageiro e de polimorfismos genéticos como fatores prognósticos em pacientes portadores de carcinoma epidermóide de cabeça e pescoço operados e submetidos à quimiorradioterapia adjuvante
Informações sobre o DOI: 10.1177/17588359211022905 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
